Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II pediatric trazodone pharmacokinetic study in insomnia associated with autism, intellectual disability, or ADHD
2018-001166-42Phase 2Terminated
- Sponsor
- Angelini Pharma
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of trazodone in Insomnia, sponsored by Angelini Pharma. Primary endpoints: Primary pharmacokinetic parameters of trazodone and Model-derived secondary PK parameters. Started Aug 2018; status: terminated.
02
Drugs
trazodone
03
Conditions
Insomnia
Beyond the preview
Go deeper on 2018-001166-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001166-42.